Polycythemia vera (PV) is technically a type of blood cancer. The World Health Organization classifies it as a myeloproliferative neoplasm, a group of cancers in which the bone marrow produces too many blood cells. That said, it behaves very differently from the cancers most people picture when they hear the word. It grows slowly, responds well to treatment, and many people live with it for decades.
The word “polycythemia” itself just means too many red blood cells, and not all forms are cancerous. The distinction matters, so it’s worth understanding where PV fits and what that classification means for your health.
Why PV Is Classified as a Neoplasm
A neoplasm is an abnormal growth of cells. In polycythemia vera, a genetic mutation causes bone marrow stem cells to overproduce red blood cells, and often white blood cells and platelets as well. About 95% of people with PV carry a specific acquired mutation in the JAK2 gene (called V617F), which essentially jams a growth signal in the “on” position. This isn’t a mutation you inherit from your parents; it develops spontaneously during your lifetime.
Because the overproduction stems from a clonal defect in the bone marrow, not from an external trigger, the WHO places PV in the same family as other myeloproliferative neoplasms. It carries an official cancer morphology code (9950/3), and cancer registries track it accordingly.
PV vs. Secondary Polycythemia
Not every case of high red blood cells is cancer. Secondary polycythemia is a completely different condition where the body ramps up red blood cell production in response to something else: living at high altitude, chronic lung disease, smoking, sleep apnea, or even testosterone therapy. In these cases, the bone marrow itself is healthy. It’s simply responding to low oxygen levels or elevated erythropoietin, the hormone that tells your marrow to make more red cells.
The key lab distinction is erythropoietin levels. In PV, erythropoietin is typically low because the bone marrow is producing red cells on its own without waiting for the signal. In secondary polycythemia, erythropoietin is high because the body is actively requesting more red cells. An erythropoietin level below 2 mIU/mL is more than 99% specific for PV, though not everyone with PV falls that low. A positive JAK2 mutation test alongside elevated hemoglobin (above 16.5 g/dL in men or 16.0 g/dL in women) generally confirms the diagnosis.
How PV Differs From Aggressive Cancers
PV is a slow-moving disease. Median survival is around 15 years from diagnosis, and for people diagnosed before age 40, it often exceeds 35 years. Those numbers don’t capture the full picture, since many patients are diagnosed later in life and may die of unrelated causes. The point is that PV is not the kind of cancer that requires urgent, aggressive intervention like chemotherapy or radiation in the way solid tumors or acute leukemias do.
The primary danger of PV isn’t the cancer itself spreading to other organs. It’s the thickened blood. Too many red blood cells make blood sluggish and prone to clotting. Before or at the time of diagnosis, 16 to 27% of patients have already experienced an arterial clot (such as a heart attack or stroke), and 7 to 12% have had a venous clot (like a deep vein thrombosis or pulmonary embolism). With treatment, the annual rate of clotting events drops to roughly 2.5 to 3%.
Symptoms That Bring People In
Many people with PV are diagnosed through a routine blood test before they notice anything wrong. When symptoms do appear, they tend to be nonspecific: headaches, dizziness, fatigue, blurred vision, and a ruddy or reddish complexion. One distinctive symptom is itching after a warm bath or shower. This water-triggered itch is strongly associated with PV, though researchers still don’t fully understand the mechanism behind it. Studies have ruled out the most obvious suspect, a type of immune cell called a mast cell, leaving the exact cause unclear.
Some people also experience burning or tingling in their hands and feet, a sensation caused by tiny clots in the smallest blood vessels. Enlarged spleen is another common finding, since the spleen works overtime filtering the excess blood cells.
How PV Is Managed
Treatment centers on keeping your hematocrit (the percentage of blood volume occupied by red cells) below 45%. This threshold was established by the CYTO-PV trial, which showed that patients held below 45% had significantly fewer heart attacks, strokes, and other clotting events compared to those managed at 45 to 50%. Some evidence suggests women may benefit from an even lower target of 42%, since they naturally have a smaller red cell mass.
The simplest way to lower hematocrit is phlebotomy, essentially the same process as donating blood. You’ll have blood drawn at regular intervals until your levels stabilize, then periodically to maintain them. For people at higher risk of clotting (generally those over 60 or with a prior clot history), doctors add a medication that slows the bone marrow’s overproduction. In the high-risk group, this combination cuts the rate of cardiovascular events roughly in half compared to phlebotomy alone. Low-dose aspirin is also standard for most patients to reduce clotting risk.
Long-Term Risks and Progression
The concern with PV over the long term is transformation into a more serious blood disease. Over 20 years, roughly 16% of patients develop post-PV myelofibrosis, a condition where scar tissue gradually replaces healthy bone marrow and blood cell production becomes increasingly impaired. The 10-year incidence of this transformation is about 12%.
A smaller number of patients develop acute myeloid leukemia, a fast-growing blood cancer that requires intensive treatment. The 10-year risk is approximately 3%, and the 15-year risk is around 8%. While these numbers are not negligible over a lifetime, they mean the large majority of PV patients will never experience either transformation. Regular blood work and checkups are how your care team monitors for early signs of progression, such as rising white blood cell counts, dropping platelet counts, or a growing spleen.
What the Cancer Label Means in Practice
Hearing that PV is a cancer can be jarring, especially when the day-to-day experience of living with it feels more like managing a chronic condition than fighting a malignancy. In practice, that’s exactly what it is for most people. You’ll have regular blood draws, possibly take a daily medication, and see a hematologist on a schedule. The cancer classification matters because it ensures PV is tracked, researched, and treated with appropriate seriousness, but it doesn’t mean your prognosis resembles what most people associate with the word “cancer.”